BDBM335701 (R)-6-(5-Chloroquinolin-7-yl)-3-(3-methyl-2-oxopiperidin-3-yl)pyridin-2(1H)-one::US9738626, 4 (free base and TFA salt)
SMILES: C[C@@]1(CCCNC1=O)c1ccc([nH]c1=O)-c1cc(Cl)c2cccnc2c1
InChI Key: InChIKey=ALGSMAYBBGCDSR-HXUWFJFHSA-N
Data: 1 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prostaglandin E2 receptor EP3 subtype (Homo sapiens (Human)) | BDBM335701 ((R)-6-(5-Chloroquinolin-7-yl)-3-(3-methyl-2-oxopip...) | PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 8.90 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description To measure the ability of test compounds in the present invention to bind to the human EP3 receptor, and therefore have the potential to antagonize P... | US Patent US9738626 (2017) BindingDB Entry DOI: 10.7270/Q2CF9S7K | |||||||||||
More data for this Ligand-Target Pair |